Eagle Pharmaceuticals Inc (NAS:EGRX)
$ 3.8 0.34 (9.8%) Market Cap: 49.24 Mil Enterprise Value: 101.23 Mil PE Ratio: 4.19 PB Ratio: 0.20 GF Score: 62/100

Eagle Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2022 / 09:30PM GMT
Release Date Price: $47.98 (-7.02%)
Ekaterina V. Knyazkova
JPMorgan Chase & Co, Research Division - Analyst

Hi, everybody. Good afternoon. I'm Ekaterina Knyazkova, from the pharma team here at JPMorgan. Pleased to be introducing Eagle. And from Eagle, we have the company's CEO, Scott Tarriff. And we'll have a Q&A session after the presentation. So if anybody has a question, feel free to submit that with the ask-a-question button, and I'll try to weave that into the Q&A.

And with that, I'll turn it over to Scott.

Scott L. Tarriff
Eagle Pharmaceuticals, Inc. - Founder, President, CEO & Director

Thank you, Ekaterina. That was very kind of you. Thank you for everybody for joining us. It's a shame we are virtual and not in San Francisco, but hello to everyone.

Let me make some opening remarks before we turn it over to Q&A. But maybe I can start out with, and there's some slides here that people can look at. If you go to Slide 4, it's titled Eagle Pharmaceuticals financial position, portfolio and pipeline. That's a good place to start. If we look just at the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot